C4 Therapeutics, Inc. (CCCC) NASDAQ

2.70

+0.07(+2.66%)

Updated at April 01 04:00PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Andrew J. Hirsch	Chief Executive Officer, President & Director	1.08M	1971
Kenneth C. Anderson	Co-Founder, Independent Director & Member of Scientific Advisory Board	45,000	1951
Jolie Siegel	Chief Legal Officer & Corporate Secretary	610,400	1976
Paige Mahaney	Chief Scientific Officer	657,342	N/A
Kendra Adams	Chief Financial Officer & Treasurer	711,215	N/A
Leonard J. Reyno	Chief Medical Officer	837,480	1962
Nathanael S. Gray	Co-Founder & Member of Scientific Advisory Board	0	N/A
Mark Mossler	Chief Accounting Officer	0	1974
Courtney Solberg	Senior Manager of Investor Relations	0	N/A
Kelly Schick	Chief People Officer	0	1980

Name

Title

Pay

Year Born

Andrew J. Hirsch

Chief Executive Officer, President & Director

1.08M

1971

Kenneth C. Anderson

Co-Founder, Independent Director & Member of Scientific Advisory Board

45,000

1951

Jolie Siegel

Chief Legal Officer & Corporate Secretary

610,400

1976

Paige Mahaney

Chief Scientific Officer

657,342

N/A

Kendra Adams

Chief Financial Officer & Treasurer

711,215

N/A

Leonard J. Reyno

Chief Medical Officer

837,480

1962

Nathanael S. Gray

Co-Founder & Member of Scientific Advisory Board

N/A

Mark Mossler

Chief Accounting Officer

1974

Courtney Solberg

Senior Manager of Investor Relations

N/A

Kelly Schick

Chief People Officer

1980

Description

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.